AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6338251
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (estramustine phosphate plus cis-platinum)
Trial: 28420122
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (18.0 g/day of NaCl)
Trial: 28420122
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet supplemented with potassium (18.0 g/day of NaCl + 4.5 g/day of KCl)
Trial: 28420122
Drug: Low-salt diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt diet (3.0 g/day of NaCl)
Trial: 26054688
Drug: Prolonged capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged capecitabine chemotherapy (1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles after eight cycles of XELOX)
Trial: 26054688
Drug: XELOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (oxaliplatin 130mg/m² on day 1 and oral capecitabine 1000mg/m² twice daily on days 1-14 of a 3-week cycle for eight cycles)
Trial: 23803900
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg dose of whole-virion inactivated H5N1 vaccine
Trial: 23803900
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg dose of whole-virion inactivated H5N1 vaccine
Trial: 11453910
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 10 or 15 J cm(‐2) on days 1 or 2 after injection.
Trial: 11453910
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with mTHPC (0.1 mg kg(‐1) intravenous injection) and light doses of 5-15 J cm(‐2).
Trial: 9236900
Drug: Post-operative brachytherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative brachytherapy (BT) with a mean dose of 57 Gy (range: 50-60)
Trial: 9236900
Drug: Post-operative external
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative external beam irradiation (EBI) with a mean dose of 50 Gy
Trial: 8325311
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (streptokinase and anistreplase)
Trial: 28333353
Drug: Atazanavir/ritonavir+lamivudine dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir+lamivudine dual therapy
Trial: 28333353
Drug: Atazanavir/ritonavir-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir-based triple therapy
Trial: 28333353
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between dual therapy and triple therapy
Trial: 26345959
Drug: DC-CIK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-CIK therapy combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Trial: 26345959
Drug: Docetaxel-cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy
Trial: 20078006
Drug: Potential solutions
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential solutions to research challenges
Trial: 12470180
Drug: DZP rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZP rectal gel
Trial: 1161345
Drug: Calcium lactate,
RxNorm normalized name: Calcium Lactate, 325 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium lactate, 800 mg/kg/24 hr in divided doses with each feed (group B)
Trial: 1161345
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium supplement (group A)
Trial: 31689708
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (160 U)
Trial: 24248687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Lapatinib and Trastuzumab (Arm C)
Trial: 19357536
Drug: Annual low
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual low dose CT scans for 5 years
Trial: 15480130
Drug: Manipulative Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative Therapy (MT)
Trial: 29068153
Drug: ciNPT (PREVENA™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciNPT (PREVENA™ Therapy)
Trial: 24535360
Drug: Propofol TCI
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol TCI + 0.8 μg/kg fentanyl
Trial: 24535360
Drug: Propofol TCI
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol TCI + 40 mg lidocaine
Trial: 17072055
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids for 2 months
Trial: 10831691
Drug: Gadobenate dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine (Gd‐BOPTA) 0.05‐mmol/kg dose administered before and after imaging
Trial: 10831691
Drug: Gadobenate dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine (Gd‐BOPTA) 0.1‐mmol/kg dose administered before and after imaging
Trial: 8800891
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics perioperatively (Group I)
Trial: 27220574
Drug: Antiarrhythmics drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmics drugs cardioversion
Trial: 20148906
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/day) and Diet alone
Trial: 18597226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard propofol titration)
Trial: 12018972
Drug: Sorbitol (1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (1305 mg)
Trial: 10622070
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg) every 12 hours for 5-10 days
Trial: 7575745
Drug: New sotalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sotalol hydrochloride tablet (160 mg)
Trial: 30026514
Drug: Jerusalem artichoke
RxNorm normalized name: JERUSALEM ARTICHOKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jerusalem artichoke and fermented soybean powder mixture (40g daily for 12 weeks)
Trial: 27528117
Drug: Androgen suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen suppression (secondary treatment)
Trial: 26875300
Drug: Low-dose ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose ferric EDTA (2.5 mg of iron)
Trial: 26875300
Drug: High-dose ferrous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ferrous lactate (10 mg of iron)
Trial: 18697192
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution inducing hyperammonemia
Trial: 18697192
Drug: p38(MAPK) agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p38(MAPK) agonist
Trial: 15813840
Drug: ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg intravenous bolus followed by oral ondansetron 8 mg twice daily for 5 days
Trial: 12560224
Drug: Randomized selection
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized selection trials evaluating several therapies based on multiple outcomes
Trial: 8478660
Drug: Doxorubicin-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-containing therapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 8478660
Drug: Doxorubicin-containing therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin-containing therapy (CHOP)
Trial: 3092659
Drug: cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (400 mg twice daily)
Trial: 30379624
Drug: Documented cardiotoxicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Documented cardiotoxicity during on-protocol therapy
Trial: 20515600
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A plus upper limb therapy programme
Trial: 20515600
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb therapy programme alone
Trial: 23342679
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A plus therapy
Trial: 16703311
Drug: iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 300 (iodine concentration: 300 mg/ml)
Trial: 16703311
Drug: iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 400 (iodine concentration: 400 mg/ml)
Trial: 16076919
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg once weekly plus calcium carbonate 500 mg daily
Trial: 16076919
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 500 mg daily
Trial: 10407719
Drug: Surviving Cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surviving Cancer Competently Intervention Program (SCCIP) - a one-day family group intervention combining cognitive-behavioral and family therapy approaches
Trial: 6767517
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 50 g of mannitol 2 hours before whole bowel irrigation (WBI)
Trial: 28741061
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for 1 week followed by 3 weeks of placebo
Trial: 27918731
Drug: Passiflora incarnata
RxNorm normalized name: Passiflora incarnata
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passiflora incarnata (260 mg)
Trial: 25140866
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg guanfacine (n=50)
Trial: 16419687
Drug: Sodium enoxaparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium enoxaparin, administered subcutaneously at a dose of 2,000 IU twice daily for 10 days
Trial: 9443710
Drug: Peptide T
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide T (2 mg, intranasally, 3 times a day for 6 months)
Trial: 7152082
Drug: Disophrol Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disophrol Syrup
Trial: 7152082
Drug: Rinomar Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinomar Syrup
Trial: 23652578
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of ranibizumab monthly for 12 months
Trial: 23652578
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of ranibizumab monthly for 3 months and then pro re nata
Trial: 23652578
Drug: high-dose 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose 2.0 mg of ranibizumab monthly for 12 months
Trial: 23652578
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter
Trial: 19389714
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg daptomycin administered as a 30 min iv infusion
Trial: 19389714
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg daptomycin administered as a 2 min iv injection
Trial: 19389714
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg daptomycin administered as a 2 min iv injection
Trial: 15036854
Drug: Cs-137 low-dose-rate
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cs-137 low-dose-rate brachytherapy (60-75 Gy at 1.4-1.8 Gy/h)
Trial: 15036854
Drug: Ra-226 low-dose-rate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ra-226 low-dose-rate brachytherapy (75 Gy at 0.5 Gy/h)
Trial: 12205256
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroxine (T4) treatment
Trial: 9220504
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl combined with midazolam
Trial: 9220504
Drug: Intramuscular meperidine‐promethazine‐chlorpromazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine‐promethazine‐chlorpromazine (MPC) compound
Trial: 2443087
Drug: 3% NaCl
RxNorm normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% NaCl (12 mL/kg)
Trial: 2443087
Drug: 7.5% NaCl/dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5% NaCl/dextran 70 (250 mL)
Trial: 12362423
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 2 gm/kg at induction and 1 gm/kg after 3 weeks
Trial: 12443959
Drug: Third-generation oral
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Third-generation oral contraceptives (specific dosage and duration not mentioned)
Trial: 1781523
Drug: Clonidine (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (two doses)
Trial: 1781523
Drug: Saline (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (inert treatment)
Trial: 7008894
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine
Trial: 28560779
Drug: S‐(‐)‐amlodipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐(‐)‐amlodipine 2.5 mg/d (low dose)
Trial: 28560779
Drug: S‐(‐)‐amlodipine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐(‐)‐amlodipine 5 mg/d (high dose)
Trial: 28560779
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between high and low dose groups
Trial: 19182688
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus medication change
Trial: 17440209
Drug: Goal-discrepant situations
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-discrepant situations (e.g., having dirty shoes)
Trial: 9489597
Drug: L-arginine (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (17 mg kg[‐1] min[‐1], infusion period 30 min)
Trial: 9489597
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II (5.0 ng kg[‐1] min[‐1], infusion period 75 min)
Trial: 8157352
Drug: Active multi-vitamin
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active multi-vitamin multi-mineral supplement
Trial: 29982631
Drug: Golimumab maintenance
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab maintenance therapy
Trial: 29982631
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to induction treatment
Trial: 29982631
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to induction treatment
Trial: 23500894
Drug: Internet-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based training (IBT) in cognitive behavioural therapy (CBT) theory, assessment and formulation (approximately three hours over the course of one month)
Trial: 21687923
Drug: Vibrating plate
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vibrating plate via reciprocation therapy
Trial: 3918683
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration fluid plus breast feeding
Trial: 3918683
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration fluid alone
Trial: 30247704
Drug: Pregnancy 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnancy 25(OH)D >125 nmol/L
Trial: 15140776
Drug: budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide 9 mg daily
Trial: 15140776
Drug: prednisolone 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone 7.5 mg daily
Trial: 15140776
Drug: budesonide 3
RxNorm normalized name: budesonide 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide 3 mg daily
Trial: 10521759
Drug: Systemic methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic methotrexate administration
Trial: 1660411
Drug: Retroperitoneal lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneal lymph node dissection (RPLND) prior to chemotherapy
Trial: 1660411
Drug: Retroperitoneal lymph
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneal lymph node dissection (RPLND) after initial chemotherapy
Trial: 6131630
Drug: Fazadinium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazadinium (1 mg . kg‐1)
Trial: 6131630
Drug: Alcuronium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium (0.2 mg . kg‐1)
Trial: 6131630
Drug: Pancuronium (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.08 mg . kg‐1)
Trial: 27571052
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of wild blueberries for 30 days
Trial: 22067666
Drug: 3% StarPharma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% StarPharma LTD 7013 gel (VivaGel)
Trial: 22067666
Drug: Placebo (carbopol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (carbopol gel without StarPharma LTD 7013)
Trial: 16418138
Drug: Optimal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal therapy (target: <120/80 mm Hg)
Trial: 16418138
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (target: <140/90 mm Hg)
Trial: 31587090
Drug: Personalised dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised dosing algorithm based on warfarin PK/PD model
Trial: 31587090
Drug: Conventional weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional weight-based dosing
Trial: 31587090
Drug: Model-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model-based dosing (Group 2)
Trial: 31587090
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing (Group 2)
Trial: 25643509
Drug: Rifaximin 1200
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 1200 mg daily divided into 3 doses for 7 days
Trial: 25643509
Drug: Lactulose syrup
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose syrup (laxolac) 90 ml daily divided into 3 doses for 7 days
Trial: 17371829
Drug: DX-619 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DX-619 (800 mg, intravenous, once daily for 4 days)
Trial: 17371829
Drug: Placebo (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous, once daily for 4 days)
Trial: 16015059
Drug: Noninvasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive therapy
Trial: 12566753
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg per day)
Trial: 12566753
Drug: Flutamide plus
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide plus oral contraceptive (250 mg flutamide + 35 microg ethinyl estradiol + 2 mg cyproterone acetate per day)